Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

FDA Issues Public Warning Re Elidel and Protopic

On February 15, 2005 the US Food and Drug Administration (FDA) Pediatric Advisory Committee recommended a "black box" warning be placed on topical calcineurin inhibitor (ElidelŪ - pimecrolimus and ProtopicŪ - tacrolimus), followed by the FDA issuing a Public Health Advisory on March 10, 2005 regarding the safety concerns.

Click on one of the titles below to read statements regarding the FDA's black box warning:

American Academy of Dermatology (AAD)
www.aad.org/public/News/NewsReleases/fda_decision.htm

Canadian Dermatology Association (CDA)
www.dermatology.ca/english/public-patients/positions_e.html

National Eczema Association for Science and Education (NEASE)
http://www.nationaleczema.org/NEASEStatementToPatients.Mar2005%20FINAL.doc

Inflammatory Skin Disease Institute
www.isdionline.org/current.htm